INT55419

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.62
First Reported 1994
Last Reported 2010
Negated 4
Speculated 2
Reported most in Abstract
Documents 19
Total Number 21
Disease Relevance 5.30
Pain Relevance 4.75

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

small molecule metabolic process (CYP1A2) oxidoreductase activity (CYP1A2) endoplasmic reticulum (CYP1A2)
enzyme binding (CYP1A2)
Anatomy Link Frequency
liver 3
plasma 1
1A2 1
CYP1A2 (Homo sapiens)
Pain Link Frequency Relevance Heat
Paracetamol 24 100.00 Very High Very High Very High
Duloxetine 218 99.80 Very High Very High Very High
sSRI 26 99.52 Very High Very High Very High
Inflammation 3 99.18 Very High Very High Very High
depression 92 98.24 Very High Very High Very High
local anesthetic 1 97.90 Very High Very High Very High
alcohol 17 97.64 Very High Very High Very High
lidocaine 15 95.96 Very High Very High Very High
Bioavailability 17 90.08 High High
antidepressant 55 89.48 High High
Disease Link Frequency Relevance Heat
Sepsis 4 99.70 Very High Very High Very High
Nicotine Addiction 36 99.28 Very High Very High Very High
INFLAMMATION 5 99.18 Very High Very High Very High
Depression 148 98.24 Very High Very High Very High
Occupational Lung Diseases 1 96.60 Very High Very High Very High
Critical Illness 18 96.04 Very High Very High Very High
Cancer 3 94.96 High High
Colon Cancer 4 94.48 High High
Liver Disease 6 91.16 High High
Lung Cancer 1 83.60 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
A thorough understanding of the functions and regulation of the CYP1A2 gene may ultimately lead to new methods for preventing or intervening in the development of certain chemically-related human cancers.
Regulation (regulation) of CYP1A2 associated with cancer
1) Confidence 0.62 Published 1995 Journal Pharmacogenetics Section Abstract Doc Link 8563766 Disease Relevance 0.09 Pain Relevance 0.07
The metabolism of the local anesthetic ropivacaine to 3-hydroxyropivacaine and (S)-2',6'-pipecoloxylidide was shown in vitro to be dependent on CYP1A2 and 3A4, respectively.
Regulation (dependent) of CYP1A2 associated with local anesthetic
2) Confidence 0.62 Published 1998 Journal Clin. Pharmacol. Ther. Section Abstract Doc Link 9834040 Disease Relevance 0 Pain Relevance 0.10
It was significantly correlated to paracetamol glucoronidation in male heavy smokers (r=0.85), suggesting an element of co-regulation of CYP1A2 and of paracetamol conjugating UDP-glucuronosyltransferase isozymes, including UGTI.6.
Regulation (co-regulation) of CYP1A2 associated with paracetamol and nicotine addiction
3) Confidence 0.60 Published 1994 Journal Pharmacogenetics Section Abstract Doc Link 7987405 Disease Relevance 0.64 Pain Relevance 0.43
The influence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronosyltransferases in man using sparteine, caffeine, and paracetamol as probes.
Regulation (influence) of CYP1A2 associated with paracetamol
4) Confidence 0.60 Published 1994 Journal Pharmacogenetics Section Title Doc Link 7987405 Disease Relevance 0.44 Pain Relevance 0.19
The acute inflammatory cascade related to sepsis may adversely affect cytochrome P450 regulation, including CYP1A2 enzyme activity [40,41], and a prolonged reduction in enzyme function in patients recovering from critical illness may have contributed to the high peak concentrations.
Spec (may) Regulation (affect) of CYP1A2 associated with inflammation, critical illness and sepsis
5) Confidence 0.55 Published 2008 Journal Crit Care Section Body Doc Link PMC2447606 Disease Relevance 0.73 Pain Relevance 0.27
The levels of other CYP proteins, including CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP2E1, were not affected by eletriptan.
Neg (not) Regulation (affected) of CYP1A2
6) Confidence 0.50 Published 2000 Journal Drug Metab. Dispos. Section Abstract Doc Link 10611140 Disease Relevance 0.06 Pain Relevance 0.15
Cytochrome CYP1A2, a liver enzyme responsible for the metabolic activation of a number of putative human carcinogens, exhibits wide inter-individual differences in activity.
Regulation (responsible) of CYP1A2 in liver
7) Confidence 0.45 Published 1997 Journal Pharmacogenetics Section Abstract Doc Link 9110357 Disease Relevance 0.07 Pain Relevance 0
A series of residues in the substrate recognition regions of CYP1A2 (e.g.
Regulation (residues) of CYP1A2
8) Confidence 0.45 Published 2009 Journal Curr. Med. Chem. Section Abstract Doc Link 19754423 Disease Relevance 0 Pain Relevance 0.12
We have examined the effects of the CYP3A4 inhibitors erythromycin and ketoconazole and the CYP1A2 inhibitor fluvoxamine on the N-deethylation, i.e. formation of monoethylglycinexylidide (MEGX), and 3-hydroxylation of lidocaine by human liver microsomes.
Spec (examined) Regulation (effects) of CYP1A2 in liver associated with lidocaine
9) Confidence 0.44 Published 1999 Journal Pharmacol. Toxicol. Section Abstract Doc Link 10608481 Disease Relevance 0 Pain Relevance 0.42
CONCLUSIONS: The population approach characterized the EK parameters and identified the low KM enzyme responsible for phenacetin O-deethylation as CYP1A2.
Regulation (responsible) of CYP1A2
10) Confidence 0.39 Published 2000 Journal Pharm. Res. Section Body Doc Link 11303964 Disease Relevance 0 Pain Relevance 0
Smoking is suspected to result in a 30% reduction of duloxetine from expected serum concentrations through its effects on CYP1A2.
Regulation (effects) of CYP1A2 associated with nicotine addiction and duloxetine
11) Confidence 0.39 Published 2010 Journal Journal of pain research Section Body Doc Link PMC3004640 Disease Relevance 0.80 Pain Relevance 0.60
Two aspects have been particularly taken into account: the changes or absence of changes in plasma/serum concentrations of concomitant drugs and the direct or indirect evidence of induction, inhibition or lack of effect on the six major human hepatic CYP isozymes (CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4), as well as on other CYP isozymes or enzyme systems.
Regulation (effect) of CYP1A2 in plasma
12) Confidence 0.37 Published 2000 Journal Fundam Clin Pharmacol Section Abstract Doc Link 11030437 Disease Relevance 0 Pain Relevance 0.20
This study confirms an enhancing effect of acetaminophen and coffee on CYP1A2 activity and suggests and inhibitory effect of estrogens, alcohol and food sources of lutein and alpha-tocopherol on this enzyme.
Regulation (effect) of CYP1A2 associated with paracetamol and alcohol
13) Confidence 0.27 Published 1997 Journal Pharmacogenetics Section Abstract Doc Link 9110357 Disease Relevance 0.25 Pain Relevance 0.26
CYP1A2 was predominantly responsible for 3'-OH-genistein formation since its formation was inhibited (>50%, p < 0.05) by a monoclonal antibody specific for CYP1A2, was correlated with CYP1A2 activities of HLM, and was catalyzed by expressed CYP1A2.
Regulation (responsible) of CYP1A2
14) Confidence 0.27 Published 2003 Journal Drug Metab. Dispos. Section Abstract Doc Link 12814970 Disease Relevance 0 Pain Relevance 0
The acute inflammatory cascade related to sepsis may adversely affect cytochrome P450 regulation, including CYP1A2 enzyme activity [40,41], and a prolonged reduction in enzyme function in patients recovering from critical illness may have contributed to the high peak concentrations.
Regulation (regulation) of CYP1A2 associated with inflammation, critical illness and sepsis
15) Confidence 0.24 Published 2008 Journal Crit Care Section Body Doc Link PMC2447606 Disease Relevance 0.73 Pain Relevance 0.27
Etravirine has no clinically relevant effect on CYP1A2 or CYP2D6.44 Etravirine may be coadministered with tenofovir, NRTIs, and the boosted protease inhibitors darunavir, lopinavir, and saquinavir, enfuvirtide and raltegravir without dosage adjustment.
Neg (no) Regulation (effect) of CYP1A2
16) Confidence 0.17 Published 2010 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2817788 Disease Relevance 0.13 Pain Relevance 0
Alteration in CYP1A2 activity, for example by smoking, may alter the requirements for theophylline among asthmatics [13] and haloperidol among psychiatric patients [14].
Regulation (Alteration) of CYP1A2 associated with nicotine addiction and occupational lung diseases
17) Confidence 0.15 Published 2008 Journal Nutr Metab (Lond) Section Body Doc Link PMC2584094 Disease Relevance 0.58 Pain Relevance 0.22
Duloxetine is eliminated through hepatic metabolism involving CYP2D6 and CYP1A2.37

Duloxetine in acute treatment of major depression

Regulation (involving) of CYP1A2 associated with depression and duloxetine
18) Confidence 0.15 Published 2010 Journal Drug design, development and therapy Section Body Doc Link PMC2846146 Disease Relevance 0.47 Pain Relevance 0.97
Agomelatine does not affect the pharmacokinetics of the bronchodilator drug theophylline, which is a substrate for CYP-1A2.
Neg (not) Regulation (affect) of CYP-1A2 in 1A2
19) Confidence 0.12 Published 2009 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2785860 Disease Relevance 0.26 Pain Relevance 0.31
We have previously shown that residue 382 affected CYP1A1 and CYP1A2 specificities with alkoxyresorufins.
Regulation (affected) of CYP1A2
20) Confidence 0.12 Published 2010 Journal Drug Metab. Dispos. Section Abstract Doc Link 20335269 Disease Relevance 0 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox